Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 19INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Chemotherapy 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Cisplatin 3sintilimab 2toripalimab 1camrelizumab 1anlotinib 1TP protocol 1Radiotherapy 1Radiation 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Fluorouracil 1Docetaxel 1Chemoradiotherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Squamous Cell Carcinoma × toripalimab × Clear all
NCT04229849 2020-01-18

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Henan Cancer Hospital

Phase 2 Unknown
164 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡